Department of Chemistry and COSDAF (Centre of Super-Diamond and Advanced Films) City University of Hong Kong, Hong Kong, 999077, China.
Key Laboratory of Biochip Technology, Biotech and Health Centre, Shenzhen Research Institute of City University of Hong Kong, Shenzhen, 518057, China.
Small Methods. 2024 Nov;8(11):e2301551. doi: 10.1002/smtd.202301551. Epub 2024 Feb 19.
Employing responsive nanoplatforms as carriers for photosensitizers represents an effective strategy to overcome the challenges associated with photodynamic therapy (PDT), including poor solubility, low bioavailability, and high systemic toxicity. Drawing inspiration from the morphology transitions in biological systems, a general approach to enhance PDT that utilizes enzyme-responsive nanoplatforms is developed. The transformation of phosphopeptide/photosensitizer co-assembled nanoparticles is first demonstrated into nanofibers when exposed to cytoplasmic enzyme alkaline phosphatase. This transition is primarily driven by alkaline phosphatase-induced changes of the nanoparticles in the hydrophilic and hydrophobic balance, and intermolecular electrostatic interactions within the nanoparticles. The resulting nanofibers exhibit improved ability of generating reactive oxygen species (ROS), intracellular accumulation, and retention in cancer cells. Furthermore, the enzyme-responsive nanoplatform is expanded to selectively target mitochondria by mitochondria-specific enzyme sirtuin 5 (SIRT5). Under the catalysis of SIRT5, the succinylated peptide/photosensitizer co-assembled nanoparticles can be transformed into nanofibers specifically within the mitochondria. The resulting nanofibers exhibit excellent capability of modulating mitochondrial activity, enhanced ROS formation, and significant anticancer efficacy via PDT. Consequently, the enzyme-instructed in situ fibrillar transformation of peptide/photosensitizers co-assembled nanoparticles provides an efficient pathway to address the challenges associated with photosensitizers. It is envisaged that this approach will further expand the toolbox for enzyme-responsive biomaterials for cancer therapy.
利用响应性纳米平台作为光敏剂的载体是克服光动力疗法(PDT)相关挑战的有效策略,这些挑战包括光敏剂的溶解度低、生物利用度低和全身毒性高。受生物系统形态转变的启发,开发了一种利用酶响应纳米平台增强 PDT 的通用方法。首先证明了在暴露于细胞质酶碱性磷酸酶时,磷肽/光敏剂共组装纳米颗粒转化为纳米纤维。这种转变主要是由碱性磷酸酶诱导纳米颗粒的亲水性和疏水性平衡以及纳米颗粒内分子间静电相互作用的变化驱动的。所得纳米纤维表现出增强的生成活性氧物种(ROS)、细胞内积累和在癌细胞中保留的能力。此外,该酶响应纳米平台通过线粒体特异性酶 SIRT5 被扩展到选择性靶向线粒体。在 SIRT5 的催化下,琥珀酰化肽/光敏剂共组装纳米颗粒可以在线粒体中特异性转化为纳米纤维。所得纳米纤维通过 PDT 表现出出色的调节线粒体活性、增强 ROS 形成和显著的抗癌功效的能力。因此,肽/光敏剂共组装纳米颗粒的酶指导原位纤维转化为解决光敏剂相关挑战提供了一种有效的途径。预计这种方法将进一步扩展用于癌症治疗的酶响应生物材料的工具包。